Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Cardiovascular Disease
100%
Efavirenz
66%
Tenofovir
66%
Prevalence
66%
Emtricitabine
66%
Insulin Resistance
66%
Efavirenz Plus Lamivudine Plus Zidovudine
33%
Lamivudine Plus Nevirapine Plus Stavudine
33%
Lamivudine Plus Nevirapine Plus Zidovudine
33%
Lamivudine Plus Stavudine
33%
High Density Lipoprotein Cholesterol
33%
Nevirapine
33%
Neuroscience
Nevirapine
100%
Human Immunodeficiency Virus
100%
Risk Factor
100%
Stavudine
66%
Efavirenz
66%
Lamivudine
66%
Lamivudine/Zidovudine
66%
Emtricitabine/Tenofovir/Efavirenz
33%
High Density Lipoprotein Cholesterol
33%
Tenofovir/Emtricitabine
33%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
100%
Cardiometabolic Risk
100%
Cardiovascular Disease
27%
Prevalence
18%
Tenofovir/Emtricitabine
18%
Efavirenz
18%
Insulin Resistance
9%
HIV/AIDS
9%
Analysis of Variance
9%
High Density Lipoprotein Cholesterol
9%
Homeostatic Model Assessment
9%
Nevirapine
9%
Efavirenz Plus Lamivudine Plus Zidovudine
9%
Lamivudine Plus Nevirapine Plus Stavudine
9%
Lamivudine Plus Stavudine
9%
Lamivudine Plus Nevirapine Plus Zidovudine
9%
Nursing and Health Professions
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
100%
Cardiovascular Disease
27%
Prevalence
18%
Emtricitabine
18%
Efavirenz
18%
Tenofovir
18%
Cholesterol Blood Level
9%
Homeostasis Model Assessment
9%
Analysis of Variance
9%
High Density Lipoprotein Cholesterol
9%
Lamivudine Plus Nevirapine Plus Stavudine
9%
Efavirenz Plus Lamivudine Plus Zidovudine
9%
Lamivudine Plus Nevirapine Plus Zidovudine
9%
Lamivudine Plus Stavudine
9%
Insulin Resistance
9%
Nevirapine
9%